In this SOHO Insider roundtable discussion, Charalambos (Babis) Andreadis, MD, MS, professor of clinical medicine at University of California, San Francisco, moderates a discussion on CELLMods in lymphoma.
The panelists include Jason Westin, MD, associate professor in the Department of Lymphoma/Myeloma at University of Texas MD Anderson Cancer Center; Loretta Nastoupil, MD, section chief of indolent lymphoma and director of clinical research at Common SpiritHealth; and Swetha Thiruvengadam, MD, assistant clinical professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
In this video, the group discusses adding novel agents to frontline chemotherapy in large B-cell lymphoma, including polatuzumab vedotin with R-CHOP and bispecific antibodies, and discuss ongoing phase 3 trials.
“I would say basically it’ll come down to what is going to be the most impactful, but also the most feasible,” Dr.Westin said on choosing frontline therapies. “I think that because the bispecific antibodies and CAR-T cells that are being studied in the frontline look very promising, they probably will have a role to play in the coming years in frontline therapy.”
Watch more videos from this discussion.
This video is being brought to you by an education grant by Bristol Myers Squibb.
